

ENDOLOGIX INC /DE/  
Form 8-K/A  
April 08, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K/A**  
**(Amendment No. 1)**

**CURRENT REPORT**  
**Pursuant to Section 13 or 15(d)**  
**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): February 3, 2016**

**ENDOLOGIX, INC.**  
**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**000-28440**  
**(Commission)**

**68-0328265**  
**(I.R.S. Employer)**

<b>of incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>
<b>2 Musick, Irvine, CA</b> <b>(Address of principal executive offices)</b>		<b>92618</b> <b>(Zip Code)</b>
<b>Registrant's telephone number, including area code: (949) 595-7200</b>		

**N/A**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ..  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ..  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ..  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ..  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Explanatory Note**

This Amendment No. 1 on Form 8-K/A (this Amendment) amends the Current Report on Form 8-K filed by Endologix, Inc. (Endologix) with the United States Securities and Exchange Commission on February 3, 2016 (the Original Report), regarding the completion of the merger with TriVascular Technologies, Inc. (TriVascular) pursuant to the Agreement and Plan of Merger, dated October 26, 2015 (the Merger Agreement), by and among Endologix, TriVascular and Teton Merger Sub, Inc., a direct wholly-owned subsidiary of Endologix (Merger Sub). Pursuant to the Merger Agreement, Merger Sub merged with and into TriVascular (the Merger), with TriVascular surviving the Merger as a direct wholly-owned subsidiary of Endologix.

The sole purpose of this Amendment is to provide the financial statements and pro forma information required by Item 9.01, which were excluded from the Original Report in reliance on paragraph (a)(4) of Item 9.01 of Form 8-K. All other items in the Original Report remain the same and are incorporated by reference into this Amendment.

**Item 9.01 Financial Statements and Exhibits.***(a) Financial Statements of Business Acquired*

The audited consolidated financial statements of TriVascular for the years ended December 31, 2014 and December 31, 2013, and for each of the three years in the period ended December 31, 2014, and the unaudited interim consolidated financial statements of TriVascular as of and for the nine months ended September 30, 2015 are filed as Exhibit 99.1 and Exhibit 99.2, respectively, to this Amendment, and are incorporated herein by reference.

*(b) Pro Forma Financial Information*

The unaudited pro forma condensed combined financial statements as of and for the year ended December 31, 2014 and as of and for the nine months ended September 30, 2015 giving effect to the Merger are filed as Exhibit 99.3 to this Amendment, and are incorporated herein by reference.

*(d) Exhibits*

## Exhibit

Number	Description
23.1	Consent of Independent Registered Public Accounting Firm (filed herewith).
99.1	Audited Consolidated Financial Statements of TriVascular Technologies, Inc. as of and for the years ended December 31, 2014 and 2013 (filed herewith).
99.2	Unaudited Consolidated Financial Statements of TriVascular Technologies, Inc. as of and for the nine months ended September 30, 2015 (filed herewith).
99.3	Unaudited Pro Forma Condensed Combined Financial Information as of and for the nine months ended September 30, 2015 (filed herewith).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENDOLOGIX, INC.

/s/ Vaseem Mahboob  
Vaseem Mahboob  
Chief Financial Officer

Date: April 8, 2016

**EXHIBIT INDEX**

Exhibit

Number	Description
23.1	Consent of Independent Registered Public Accounting Firm (filed herewith).
99.1	Audited Consolidated Financial Statements of TriVascular Technologies, Inc. as of and for the years ended December 31, 2014 and 2013 (filed herewith).
99.2	Unaudited Consolidated Financial Statements of TriVascular Technologies, Inc. as of and for the nine months ended September 30, 2015 (filed herewith).
99.3	Unaudited Pro Forma Condensed Combined Financial Information as of and for the nine months ended September 30, 2015 (filed herewith).